 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Atara Biotherapeutics, Inc. Nasdaq: ATRA, a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will disclose its completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis via press release after market close on Tuesday, July 12, 2022. Following the release, the Company will hos 